«Adeno-associated viruses have become popular vectors for the delivery of gene therapies. But, despite their relatively safe profile, they can trigger some unwanted immune responses, which may reduce treatment efficacy or, worse, cause serious side effects.»

«Now, a Harvard University team led by renowned geneticist and serial biotech entrepreneur George Church, Ph.D., has developed a way to «cloak» AAVs from immune surveillance by inhibiting the activation of a DNA-sensing protein called Toll-like receptor 9 (TLR9). The engineered vectors elicited significantly reduced inflammation and T-cell responses while at the same time improving gene expression in mouse and pig models, according to results published in Science Translational Medicine.»

Article written by Angus Liu



Fierce Biotech